PFE — PFIZER INC

NYSE · Health Care · Pharmaceuticals · CIK 78003 ·
Last close
$24.29
Market Cap
$138.44B
52W High
$28.28
52W Low
$23.62
ADV30
41,503,750
Next earnings
2026-08-04
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 14,450,000,000 10,902,000,000 4,131,000,000 2,687,000,000 207,618,000,000 1,703,000,000 117,214,000,000
Dec 2025 17,557,000,000 12,285,000,000 3,475,000,000 -1,648,000,000 208,160,000,000 1,142,000,000 121,385,000,000
Sep 2025 16,654,000,000 12,482,000,000 4,137,000,000 3,541,000,000 208,731,000,000 1,343,000,000 115,635,000,000
Jun 2025 14,653,000,000 10,875,000,000 3,765,000,000 2,910,000,000 206,095,000,000 1,638,000,000 117,083,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$11,961,000,000
Investing CF
$-3,841,000,000
Financing CF
$-7,932,000,000
CapEx
$-2,501,000,000
Dividends Paid
$-9,779,000,000
Buybacks
EPS Diluted TTM
$1.31
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$117,238,000,000
Inventory
$10,667,000,000
Receivables
$16,173,000,000
ST Investments
$11,372,000,000
EBIT TTM
$10,591,000,000
Pretax Income TTM
$7,906,000,000
Interest Exp TTM
$2,685,000,000
Analysts
27

Yahoo Snapshot (yfinance, live)

Total Revenue
$63,315,001,344
EBITDA
$25,460,000,768
Free Cash Flow
$12,376,625,152
Enterprise Value
$190,392,500,224
Total Cash
$13,080,999,936
Total Debt
$64,731,000,832
Shares Out
5,699,444,169
Trailing EPS
$1.31
Book Value
$15.81
ROE
8.3%
ROA
5.7%
Div Yield
7.08%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 62,579,000,000 15,794,000,000 7,771,000,000 208,160,000,000 121,385,000,000 11,704,000,000
Dec 2024 63,627,000,000 14,830,000,000 8,031,000,000 213,396,000,000 124,899,000,000 12,744,000,000
Dec 2023 59,554,000,000 4,223,000,000 2,119,000,000 226,501,000,000 137,213,000,000 8,700,000,000
Dec 2022 101,175,000,000 37,164,000,000 31,372,000,000 197,205,000,000 101,289,000,000 29,267,000,000

TTM Snapshot

Revenues TTM
$77,866,000,000
NetIncome TTM
$18,837,000,000
OpCashFlow TTM
$0
Assets (Latest)
$213,396,000,000
Forward EPS
$2.83

Max Pain — expiry 2026-07-02

max pain strike: $24.50 · spot: $24.19 · call oi: 26,540 · put oi: 15,405
Expected Move to 2026-07-02: ±$0.45 (1.88%) — implied range $23.74$24.65 · ATM straddle on $24.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VRTX VERTEX PHARMACEUTICALS INC / MA $124.70B $491.34
NONOF NOVO NORDISK A S $159.42B $47.56
NVO NOVO NORDISK A S $161.13B $48.07
BMY BRISTOL MYERS SQUIBB CO $117.46B $57.52
ABT ABBOTT LABORATORIES $163.94B $94.12

News headlines (Yahoo Finance, 1h cache)

3 No-Brainer Dividend Stocks to Buy Right Now
2026-06-29 16:03 · Yahoo
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
2026-06-29 14:51 · Yahoo
Edison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech Companies
2026-06-29 13:36 · Yahoo
China surpassing Europe in Drug Innovation and Development, Pfizer Inc. (PFE) Executive says
2026-06-28 19:58 · Yahoo
A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?
2026-06-28 08:50 · Yahoo
Pfizer (PFE) Dismissed From Generic Drug Price Fixing Lawsuit
2026-06-27 20:07 · Yahoo
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
2026-06-27 19:35 · Yahoo
Here's How Many Shares of Pfizer You Must Own to Get $5,000 in Yearly Dividends
2026-06-27 16:07 · Yahoo
Alphabet Is Joining the Dow Jones Industrial Average. 3 Surprising Reasons Why SpaceX Could Be Next.
2026-06-27 14:20 · Yahoo
AbbVie Stock's Growth Story Has One Question Mark
2026-06-26 16:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.